Gene expression vaccine

Details Gene expression vaccine Gene expression vaccine

2006-10-10

2006-10-10

Campell, Bruce R. (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069500, C435S069700, C435S235100, C435S236000, C435S239000, C435S455000, C435S320100, C424S093200, C424S187100, C424S185100, C424S186100, C424S202100, C424S204100, C424S211100, C424S234100, C424S489000, C424S490000, C424S491000, C514S002600, C514S008100, C514S04400A, C514S055000, C530S300000, C530S350000, C536S023100, C536S023700, C536S023720, C536S020000

Reexamination Certificate

active

07118888

ABSTRACT:
An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-γ production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.

REFERENCES:
patent: 5882651 (1999-03-01), Murphy et al.
patent: 6184037 (2001-02-01), Rolland et al.
patent: 6264957 (2001-07-01), Collins
patent: 6489306 (2002-12-01), Mohapatra et al.
patent: 6900299 (2005-05-01), Mohapatra et al.
patent: 2001/0006951 (2001-07-01), Mohapatra et al.
patent: 2003/0198624 (2003-10-01), Mohapatra et al.
patent: 2005/0159385 (2005-07-01), Mohapatra
patent: 2005/0266093 (2005-12-01), Mohapatra
patent: 2005/0272650 (2005-12-01), Mohapatra
patent: WO 90/09780 (1990-09-01), None
patent: WO85/04185 (1987-07-01), None
patent: WO 97/20576 (1997-06-01), None
patent: WO 98/02457 (1998-01-01), None
patent: WO 98/02457 (1998-01-01), None
patent: WO 99/36089 (1999-07-01), None
patent: WO 02/34287 (2002-05-01), None
patent: WO 02/44334 (2002-06-01), None
patent: WO 03/028759 (2003-04-01), None
Stedman's Online Medical Dictionary, 27th Ed, home http://www.stedmans.com, 2003-definition “antigen”.
Leong et al., Journal of Controlled Release, vol. 53, pp. 183-193 (1998).
Collins et al., Proceedings of the National Academy of Sciences, USA, vol. 92, pp. 11563-11567 (1995).
HSu et al., Journal of General Virology, vol. 80, pp. 1401-1405 (1999).
Simmons et al., Journal of Immunology, vol. 166 No. 2, pp. 1106-1113 (Jan. 2001).
Wright et al., Journal of Infectious Diseases, vol. 182 No. 5, pp. 1331-1342 (Sep. 2000).
Montgomery et al., Pharmacology and Therapeutics, vol. 74 No. 2, pp. 195-205 (1997).
Pastey et al., Journal of General Virology, vol. 76 No. 1, pp. 193-197 (Jan. 1995).
Chanock et al.,, “Serious Respiratory Tract Disease Caused by Respiratory Syncytial Virus: Prospects for Improved Therapy and Effective Immunization”, Pediatrics, 1992, pp. 137-141.
Roy et al., “Oral Gene Delivery With Chitosan-DNA Nanoparticles Generates Immunologic Protection in a Murine Model of Peanut Allergy”, Nature Medicine, 1999, pp. 387-390.
Behera et al., “Blocking Intercellular Adhesion Molecule-1 on Human Epithelial Cells Decreases Respiratory Syncytial Virus Infection”, 2001, pp. 188-195.
Matsuse et al., “Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness”, 2000, pp. 6583-6592.
Matsuo et al., “Induction of Innate Immunity by Nasal Influenza Vaccine Administered in Combination with an Adjuvant (Cholera Toxin)”, Vaccine, 2000, pp. 2713-2722.
Connors et al., “Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived”,J Virol65. 1634,1991.
Wyatt et al, “Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA”,Vaccine18:392, 1999.
Domachowske et al., “Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment,”Clin Microbiol Rev12:298, 1999).
Brandenburg et al., “Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development,”Vaccine19:2769, 2001.
Groothuis et al., “Use of Intravenous Gamma Globulin To Passively Immunize High-Risk Children against Respiratory Syncytial Virus: Safety and Pharmacokinetics,”Antimicrobial Agents and Chemotherapy, Jul. 1991, pp. 1469-1473.
Hemming et al., “Hyperimmune Globulins in Prevention and Treatment of Respiratory Syncytial Virus Infections,”Clin Microbiol Rev.Jan. 1995;8(1):22-33. Review.
Li et al, “Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate,”Virology. Mar. 30, 2000; 269(1): 54-65.
Li et al, “Protection against respiratory syncytial virus infection by DNA immunization,”J Exp MedAug. 17, 1998;188(4):681-8.
Prince et al, “Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats,”J Virol.Nov. 2000;74(22): 10287-92.
Guy et al, “Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine,”Vaccine19:1794, 2001.
Anderson, L. “Respiratory syncytial virus vaccines for otitis media”Vaccine, 2001, 19:S59-S65.
Kumar, M. et al. “A RSV Genome Chitosan Nanosphere (RGCN) Vaccine Against Respiratory Syncytial Virus (RSV) Infection”J. Allergy and Clin. Immuno., Feb. 2001, 2(107):S251 (abstract).
Whitehead, S. S. et al. “Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 of SH Gene is Attenuated in Chimpanzees”J. Virology, Apr. 1999, 73(4):3438-3442.
Mao, H.Q. et al. “DNA-chitosan nanoshperes for gene delivery” in International Symposium on Controlled Release of Bioactive Materials, 23(1996), Kyoto, Japan, Controlled Release Society; abstract No. 4138, p. 401.
Mao, H.Q. et al. “DNA-chitosan nanospheres: derivatization and storage stability” in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract No. 6016, p. 671.
Walsh, S.M. et al. “Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis” in Proceedings of the International Conference on Controlled Release of Bioactive Agents, 24(1997), Stockholm, Sweden, abstract No. 238, p. 75.
Truong-Le, V.L. et al. “Delivery of DNA vaccine using gelatin-DNA nanospheres” In International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract No. 219, p. 39.
Roy, K. et al. “DNA-chitosan nanospheres: transfection efficiency and cellular uptake” in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract No. 6017, p. 673.
Behera, A. et al. “Adenovirus-mediated interferon γgene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling”Human Gene Therapy, 2002, 13:1697-1709.
Doolan, D. et al. “Utilization of genomic sequence information to develop malaria vaccines”J. Exp. Biol., 2003, 206:3789-3802.
Dumonteil, E. et al. “DNA vaccines induce partial protection againstLeishmania mexicana”Vaccine, 2003, 21:2161-2168.
Hellermann, G. and Mohapatra, S. “Genetic therapy: on the brink of a new future”Genetic Vaccines and Therapy, 2003, 1:1-2.
Kumar, M. et al. “Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma”genetic Vaccines and Therapy, 2003, 1:1-10.
Kumar, M.N.V.R. et al. “Cationic poly(lactide-co-glycolide) nanoparticles as efficientin vivogene transfection agents”J. Nanocsci. Nanotech, 2004, 4(8):1-5.
Kumar, M.N.V.R. et al. “Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiencyin vitroandin vivo”J. Nanosci. Nanotech., 2004, 4(7):1-6.
Kumar, M.N.V.R. et al. “Nanoparticle-mediated gene delivery: state of the art”Expert Opin. Biol. Ther., 2004, 4(8):1-12 (author's proof; pp. 1213-1224 as published).
Kumar, M. et al. “Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection”Human Gene Therapy, 2002, 13:1415-1425.
Kumar, M. et al. “Intranasal IFN-γgene transfer protects BALB/c mice against respiratory syncytial virus infectionȁ

Affiliated with

Also associated with

Rating

Gene expression vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene expression vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616657